FDA Approves Gazyva as First Drug for Primary Membranous Nephropathy
The FDA has approved Genentech's Gazyva for adults with primary membranous nephropathy, a rare autoimmune kidney disease with no previously approved drug. In a 142-patient trial, complete remission at two years was far more common than with tacrolimus, an off-label standard option.
The FDA Promises a Custom-Fit Rulebook for Rare Disease Drugs. Patients Should Read the Fine Print.
The FDA’s new Rare Disease Framework Initiative promises evidence standards tailored to tiny patient populations. What it covers, how to weigh in on October 28, and the questions it leaves open.